Revolution Medicines, Inc. (RVMD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $141.59: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.02; Below-average business quality; Negative price momentum.
Revolution Medicines is a clinical-stage oncology company developing RAS(ON) Inhibitors for RAS-addicted cancers, with daraxonrasib (multi-selective, FDA Breakthrough Therapy for PDAC), zoldonrasib (G12D-selective, Breakthrough Therapy for NSCLC), and elironrasib... Read more
Sell if holding. Engine safety override at $141.59: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.02; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinedaraxonrasib (RMC-6236)10-K Item 1A: 'certain assets related to the RMC-6236 Products'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $141.59: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.02; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $131.93. Score 4.2/10, moderate confidence.
Take-profit target: $156.87 (+10.6% upside). Prior stop was $131.93. Stop-loss: $131.93.
Concentration risk — Pipeline: daraxonrasib (RMC-6236); Quality below floor (1.7 < 4.0).
Revolution Medicines, Inc. trades at a P/E of N/A (forward -26.8). TrendMatrix value score: 6.0/10. Verdict: Sell.
27 analysts cover RVMD with a consensus score of 4.4/5. Average price target: $174.
What does Revolution Medicines, Inc. do?Revolution Medicines is a clinical-stage oncology company developing RAS(ON) Inhibitors for RAS-addicted cancers, with...
Revolution Medicines is a clinical-stage oncology company developing RAS(ON) Inhibitors for RAS-addicted cancers, with daraxonrasib (multi-selective, FDA Breakthrough Therapy for PDAC), zoldonrasib (G12D-selective, Breakthrough Therapy for NSCLC), and elironrasib (G12C-selective, Breakthrough Therapy for NSCLC) all in Phase 3 registrational trials. The company has no revenue from product sales; as of December 31, 2025, cash was $2.0 billion and accumulated deficit was $2.9 billion. In June 2025, Royalty Pharma provided $250M under a Royalty Purchase Agreement linked to daraxonrasib.